Many patients on chronic opioid therapy suffer from constipation, one of the most common side effect of opioids. Movantik (naloxegol) is an opioid antagonist that is recently introduced in the market to treat opioid-induced constipation and contains naloxegol as the active ingredient. Naloxegol is ...
Naloxegol, an oral peripheral μ-opioid receptor antagonist, is associated with significantly increased bowel movements compared with placebo in patients with opioid-induced constipation, and it doesn't reduce opioid mediated analgesia, new research shows. The results of 2 studies "confirm the efficacy"...
Sostek, MarkOfficial journal of the American College of Gastroenterology | ACGChey W, Tack J, Webster L, et al. Naloxegol symptom responder rates in patients with opioid-induced constipation: results from two prospective, randomized controlled trials. Am J Gastroenterol. 2013;108:S570....
Efficacy and safety of naloxegol in patients with opioid-induced constipation: results from 2 prospective, randomized, controlled trials. Gastroenterology. 2013;144(5 suppl 1):S159–S160.Tack J, Lappalainen J, Diva U et al. Efficacy and safety of naloxegol in patients with opioid-induced ...
Conclusion (s) Implementing a structured regime with Naloxegol prescription on Day 3 BNO at its heart provides for a significant improvement in constipation within Orthogeriatrics.doi:10.1093/ageing/afac126.087Hira, SFomani, NAge & Ageing
CONSTIPATIONANALGESIASYMPTOMSIRRITABLE colonCANCER painThis study evaluates the onset, magnitude, and consistency of improvement of opioid-induced constipation (OIC) symptoms with naloxegol treatment.Methods: This was a pooled analysis of two Phase 3, double-blind, randomized, placebo-contr...
AstraZeneca announces results from long-term safety trial of naloxegol in patients with opioid-induced constipation - European Pharmaceutical ReviewAstraZeneca,Briggs Morrison
Objective To summarize results from pain and opioid use assessments with naloxegol in adults with opioid‐induced constipation (OIC) and chronic noncancer pain. Methods Two phase 3 randomized, double‐blind, 12‐week studies evaluated the efficacy and safety of oral naloxegol (12.5 or 25 mg daily...
Patients were randomised 2:1 to receive naloxegol 25 mg/day or usual-care (UC; investigator-chosen laxative regimen) treatment for OIC. RESULTS: The safety set comprised 804 patients (naloxegol, n = 534; UC, n = 270). Mean exposure duration was 268 days with naloxegol and 297...
The majority of studies evaluating OIBD focus on constipation experienced in approximately 60% of patients. Nevertheless, other presentations of OIBD seem to be equally frequent. Furthermore, laxative treatment is often insufficient, which in many patients results in decreased quality ...